Safrole

CAS RN: 94-59-7

Treatment Overview

0.4.2 ORAL/PARENTERAL EXPOSURE
  • A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    • 1) Treatment is symptomatic and supportive. Limited experience. Monitor vital signs. Monitor fluid and electrolytes as necessary. Administer IV fluids and electrolytes to replace significant gastrointestinal loss. Minor fluctuations in blood pressure (ie, hypotension) may not require intervention.
  • B) MANAGEMENT OF SEVERE TOXICITY
    • 1) Treatment is symptomatic and supportive. Limited experience. Minor vital signs. Monitor CNS and respiratory function. Support airway and ensure adequate ventilation as necessary. Treat severe hypotension with IV 0.9% NaCl at 10 to 20 mL/kg. Add dopamine or norepinephrine if unresponsive to fluids.
  • C) DECONTAMINATION
    • 1) PREHOSPITAL: Emesis should not be induced after a significant ingestion of sassafras oil because of the risk of aspiration. DERMAL: Dermal exposure to sassafras oil should only cause minor irritation. Remove clothing and provide adequate washing of the skin with soap and water. OCULAR: Eye exposure to sassafras oil may cause irritation. Exposed eyes should be irrigated with copious amounts of room temperature water for at least 15 minutes.
    • 2) HOSPITAL: Emesis should not be induced after a significant ingestion of sassafras oil because of the risk of aspiration. DERMAL: Dermal exposure to sassafras oil should only cause minor irritation. Remove clothing and provide adequate washing of the skin with soap and water. A physician may need to examine the area if irritation or pain persists. OCULAR: Eye exposure to sassafras oil may cause irritation. Exposed eyes should be irrigated with copious amounts of room temperature water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persists after 15 minutes of irrigation, an ophthalmologic examination should be performed.
  • D) ANTIDOTE
    • 1) There is no specific antidote.
  • E) AIRWAY MANAGEMENT
    • 1) Airway support is unlikely to be necessary following a minor or taste exposure. Assess airway to rule out possible aspiration or respiratory insufficiency and ensure adequate ventilation.
  • F) ENHANCED ELIMINATION
    • 1) At the time of this review, there was no information on measures to enhance the elimination of sassafras oil or safrole.
  • G) PITFALLS
    • 1) Failure to obtain an adequate history of exposure. Failure to determine the active ingredients found in sassafras oil (ie, found in health food stores, purchased online).
  • H) PATIENT DISPOSITION
    • 1) HOME CRITERIA: Ingestion of sassafras teas OR a taste ingestion of sassafras oil can be observed at home. The ingestion of leaves and twigs from sassafras albidum may pose a choking hazard but significant toxicity from direct ingestion of the plant material has not been reported. Patients that develop more than mild gastrointestinal symptoms may need to be observed in a healthcare facility.
    • 2) OBSERVATION CRITERIA: Patients that developed persistent gastrointestinal symptoms may need to be treated and observed until clearly improving. Patients with persistent symptoms (ie, hypotension, CNS symptoms) despite treatment may require inpatient admission.
    • 3) ADMISSION CRITERIA: Due to limited experience with sassafras oil, patients that develop significant CNS or cardiovascular symptoms may require hospital admission for further monitoring and treatment.
    • 4) CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity or in whom the diagnosis is not clear.
0.4.4 EYE EXPOSURE
  • A) Exposed eyes should be irrigated with copious amounts of room temperature water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed.
0.4.5 DERMAL EXPOSURE
  • A) OVERVIEW
    • 1) Wash the exposed area thoroughly with soap and water. A physician may need to examine the area if irritation or pain persists.
Find more information on this substance at: PubChem, PubMed